Ionis Pharmaceuticals Inc’s recently made public that its Officer Monia Brett P acquired Company’s shares for reported $30268.0 on Oct 06 ’25. In the deal valued at $69.26 per share,437 shares were bought.
Then, Baroldi Joseph bought 1,625 shares, generating $112,725 in total proceeds.
Before that, Swayze Eric bought 6,849 shares. Ionis Pharmaceuticals Inc shares valued at $472,718 were divested by the Officer at a price of $69.02 per share.
Goldman upgraded its Ionis Pharmaceuticals Inc [IONS] rating to a Neutral from a a Sell in a research note published recently. A number of analysts have revised their coverage, including BMO Capital Markets’s analysts, who increased its forecast for the stock in early September from “a Market perform” to “an Outperform”. Morgan Stanley also remained covering IONS and has increased its forecast on July 31, 2025 with a “an Overweight” recommendation from previously “an Equal-weight” rating. Barclays revised its rating on July 01, 2025. It rated IONS as “an Overweight” which previously was an “an Equal weight”.
Price Performance Review of IONS
On Monday, Ionis Pharmaceuticals Inc [NASDAQ:IONS] saw its stock fall -0.19% to $69.02. Over the last five days, the stock has gained 7.59%. Ionis Pharmaceuticals Inc shares have risen nearly 75.27% since the year began. Nevertheless, the stocks have risen 97.43% over the past one year. While a 52-week high of $69.25 was reached on 10/06/25, a 52-week low of $23.95 was recorded on 04/09/25.
Levels Of Support And Resistance For IONS Stock
The 24-hour chart illustrates a support level at 68.53, which if violated will result in even more drops to 68.05. On the upside, there is a resistance level at 69.82. A further resistance level may holdings at 70.63.
How much short interest is there in Ionis Pharmaceuticals Inc?
A steep rise in short interest was recorded in Ionis Pharmaceuticals Inc stocks on 2025-09-15, growing by 1.19 million shares to a total of 11.97 million shares. Yahoo Finance data shows the prior-month short interest on 2025-08-15 was 10.79 million shares. There was a rise of 9.92%, which implies that there is a positive sentiment for the stock.
The most recent change occurred on April 07, 2025 when H.C. Wainwright began covering the stock and recommended ‘”a Buy”‘ rating along with a $45 price target.
